GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials
Pooled result · Optic nerve/vision-threatening serious adverse events (composite)Result — go to the resultOdds ratio 1.20 95% CI 0.73–1.97Authors' conclusion
Based on a large number of patients who contributed to a meta-analysis of RCTs involving participants with type 2 diabetes and cardiometabolic disease, GLP-1 RAs were not associated with an increased risk of optic nerve/vision-threatening events.
Study context
- Population
- Patients with T2D or cardiometabolic diseases in randomized controlled trials (RCTs) of GLP-1 RAs; T2D in 76.4%
- Participants
- 83,288 patients20 RCTs
- Comparison
- GLP-1 RA vs comparator
- Outcome
- Composite of:
- Optic nerve
- Vision-threatening serious adverse events (ischemic optic neuropathy (ION), ocular ischemic syndrome, papilledema, blindness, blurred vision, visual impairment, reduced visual acuity)
- Follow-up
- Mean 2.97 years
Methodological detailsPRISMA, RCTs reported vision-threatening events as adverse events rather than as prespecified outcomes
- PRISMA
- RCTs reported vision-threatening events as adverse events rather than as prespecified outcomes
Pooled result
As reported in the abstract
Optic nerve/vision-threatening serious adverse events (composite)
Odds ratio
1.20
95% CI 0.73–1.97
GLP-1 RAvs Comparator
OR 1.20 (95% CI 0.73–1.97)
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| IONGLP-1 RAvs Comparator | 1.50 (0.49–4.63) | |
| Vision loss/disturbance eventsGLP-1 RAvs Comparator | 1.08 (0.60–1.94) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials. Diabetes Care. Published 26 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →